News >

Long Shares Insight on Pivotal Data in BRAF-Mutant Melanoma

Caroline Seymour
Published: Wednesday, Jul 10, 2019

Georgina V. Long, BSc, PhD, MBBS

Georgina V. Long, BSc, PhD, MBBS
As the longest follow-up of treatment-naïve patients with BRAF V600E-mutant, unresectable or metastatic melanoma treated with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist), the pooled analysis of the phase III COMBI-v and COMBI-d trials provides evidence to support that that the doublet can result in lasting benefit for this patient population, explained Georgina V. Long, BSc, PhD, MBBS, FRACP.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x